Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Los Alamos, NM

    Search
    Los Alamos, NM
    Show Map
    Map View
    Los Alamos, NM

    Popular Searches

    By Condition

    Depression Clinical Trials in New Mexico

    Anxiety Clinical Trials in New Mexico

    Schizophrenia Clinical Trials in New Mexico

    ADHD Clinical Trials in New Mexico

    Bipolar Disorder Clinical Trials in New Mexico

    Multiple Sclerosis Clinical Trials in New Mexico

    Autism Clinical Trials in New Mexico

    Treatment Resistant Depression Clinical Trials in New Mexico

    Borderline Personality Disorder Clinical Trials in New Mexico

    Social Anxiety Disorder Clinical Trials in New Mexico

    Parkinson's Disease Clinical Trials in New Mexico

    Alzheimer's Disease Clinical Trials in New Mexico

    By Location

    Clinical Trials near Albuquerque, NM

    Clinical Trials near Santa Fe, NM

    Clinical Trials near Las Cruces, NM

    Clinical Trials near Farmington, NM

    Clinical Trials near Rio Rancho, NM

    Clinical Trials near Gallup, NM

    Clinical Trials near Shiprock, NM

    Clinical Trials near Alburquerque, NM

    Clinical Trials near Los Alamos, NM

    Clinical Trials near Sante Fe, NM

    Clinical Trials near Alamogordo, NM

    Clinical Trials near Taos, NM

    Other People Viewed

    By Subject

    Top Clinical Trials near Astoria, NY

    Top Attention-Deficit/Hyperactivity Disorder (ADHD) Clinical Trials near San Diego, CA

    194 Clinical Trials near Fairfield, CT

    Top Treatment for Intervention Clinical Trials

    Top Clinical Trials near Hawaiian Gardens, CA

    Top Clinical Trials near Fountain Inn, SC

    Top Clinical Trials near Horsham, PA

    Top Clinical Trials near Bethany, OK

    24 Weight Loss Trials near Chicago, IL

    Top Clinical Trials near Westwood, KS

    Top Clinical Trials near Germantown, TN

    Top Clinical Trials near Granada Hills, CA

    By Trial

    BMS-986463 for Advanced Cancer

    Cancer Prevention Education for Breast and Cervical Cancer

    Indego™ Exoskeleton for Spinal Cord Injury

    Antibiotic Strategies for Pneumonia in Children

    GS-1720 + GS-4182 for HIV

    MobiusHD® for Heart Failure

    Combination Chemotherapy + Radiation for Esophageal Cancer

    Rituximab + Bendamustine/Ibrutinib for Chronic Lymphocytic Leukemia

    Yoga for Cognitive Impairment in Heart Failure

    Surgery for Pancreatic Cancer with Liver Metastases

    Online Cognitive Behavioural Therapy for Student Mental Health

    Motivational Interviewing for Increasing Physical Activity

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      188 Clinical Trials near Los Alamos, NM

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Relugolix Combination Therapy for Birth Control

      Albuquerque, New Mexico
      The purpose of this study is to assess the contraceptive efficacy of relugolix combination therapy.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:18 - 50
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Infertility, Thromboembolic Events, Others
      Must Not Be Taking:Isotretinoin, Thalidomide

      1020 Participants Needed

      RGX-314 Gene Therapy for Wet Age-Related Macular Degeneration

      Albuquerque, New Mexico
      This trial is testing a new one-time gene therapy called RGX-314 for patients with wet AMD. It aims to help the eye make its own medicine to stop harmful blood vessels from causing vision loss. This could reduce the need for regular injections. RGX-314 modifies the retina's cells to create a treatment that may only be needed once.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3
      Age:50 - 89

      Key Eligibility Criteria

      Disqualifiers:Retinal Detachment, Advanced Glaucoma, Others
      Must Be Taking:Anti-VEGF

      630 Participants Needed

      Ferric Citrate for Chronic Kidney Disease

      Albuquerque, New Mexico
      This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:6 - 16

      Key Eligibility Criteria

      Disqualifiers:Active GI Disorder, Liver Transaminases, Organ Transplant, Others

      45 Participants Needed

      Darolutamide + Standard Therapy for Prostate Cancer

      Albuquerque, New Mexico
      This trial is testing darolutamide, a new drug added to standard hormone therapy, in men with high-risk localized prostate cancer undergoing radiation. The goal is to see if this combination can better prevent the cancer from coming back and spreading compared to current treatments. Darolutamide works by blocking male hormones that help cancer grow, potentially reducing death rates from prostate cancer.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Metastatic Disease, PSA > 100, Others
      Must Be Taking:LHRHA

      1100 Participants Needed

      Olvi-Vec + Chemotherapy for Ovarian Cancer

      Albuquerque, New Mexico
      The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II VIRO-15 trial with promising objective response rate and progression-free survival observed in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer. The phase II results also showed that the intra-peritoneal route of delivery was efficient in generating tumor cell killing and immune activation, and led to clinical reversal of platinum-resistance or refractoriness in this difficult-to-treat patient population.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:CNS Metastasis, HIV, Hepatitis, Others
      Must Not Be Taking:Antivirals, Immunosuppressants, Steroids

      186 Participants Needed

      Atacicept for IgA Nephropathy

      Albuquerque, New Mexico
      This trial is testing a medication called atacicept for people with a kidney disease called IgA Nephropathy who still have too much protein in their urine despite other treatments. Atacicept works by calming the immune system to help reduce protein levels in the urine. The study will compare atacicept to see if it is effective and safe.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Secondary IgAN, Nephrotic Syndrome, Uncontrolled Diabetes, Others
      Must Be Taking:RAASi

      376 Participants Needed

      Radiation Therapy + Atezolizumab for Small Cell Lung Cancer

      Albuquerque, New Mexico
      This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation therapy in addition to atezolizumab may extend the time without extensive small cell lung cancer growing or spreading compared to atezolizumab alone.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, Liver Disease, Others
      Must Be Taking:Atezolizumab

      138 Participants Needed

      Long-term Safety and Efficacy of Bimatoprost SR for Glaucoma

      Albuquerque, New Mexico
      This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Other Drug Studies, Others
      Must Be Taking:Bimatoprost SR

      455 Participants Needed

      Naltrexone + Bupropion for Obesity

      Albuquerque, New Mexico
      This trial studies the effects of a medication combination (naltrexone and bupropion) on heart health. It targets patients to see if this treatment increases the risk of major heart problems. The study also includes advice on diet and exercise. Naltrexone and bupropion have been used in combination for weight loss, but they have been associated with various adverse effects, including neuropsychiatric disorders and cardiovascular risks.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 4

      Key Eligibility Criteria

      Disqualifiers:Recent MI, Stroke, Hypertension, Others
      Must Not Be Taking:Bupropion, Opioids, MAOIs, Others

      8600 Participants Needed

      Ribociclib + Letrozole for Ovarian Cancer

      Albuquerque, New Mexico
      The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Concurrent Malignancy, CNS Involvement, Others
      Must Be Taking:Hormonal Suppression

      51 Participants Needed

      Disitamab Vedotin for HER2-Positive Cancer

      Albuquerque, New Mexico
      This trial is testing a new drug called disitamab vedotin (DV) on patients with advanced or metastatic cancers that have a specific marker called HER2. The drug works by finding and attaching to cancer cells, then delivering a substance to kill them. The study aims to see if DV is effective and safe for these patients. Disitamab vedotin is an antibody-drug conjugate designed for targeting HER2 that has been approved for urothelial carcinoma and gastric cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancy, CNS Metastasis, Others
      Must Be Taking:Platinum-based, Anti-PD(L)1, PARP Inhibitors

      120 Participants Needed

      4D-150 for Diabetic Macular Edema

      Albuquerque, New Mexico
      Phase 2 randomized, active-controlled, double-masked, dose-ranging trial in adults with Diabetic Macular Edema (DME).
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Macular Edema, Gene Therapy, Others
      Must Be Taking:Aflibercept

      72 Participants Needed

      Obeticholic Acid + Bezafibrate for Primary Biliary Cholangitis

      Albuquerque, New Mexico
      Study to determine the effect of the investigational drug bezafibrate (BZF) alone and in combination with the investigational drug obeticholic acid (OCA) in participants with Primary Biliary Cholangitis (PBC).

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other Liver Diseases, Gallbladder Disease, Pregnancy, Others
      Must Be Taking:Ursodeoxycholic Acid

      60 Participants Needed

      ZN-c3 + Niraparib for Ovarian Cancer

      Albuquerque, New Mexico
      This trial is testing a new drug called ZN-c3, alone and with niraparib, in patients with a type of ovarian cancer that doesn't respond to usual treatments. The drugs work by stopping cancer cell growth and preventing the cells from repairing themselves. Niraparib is an oral medication approved for use in ovarian cancer patients.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      117 Participants Needed

      Triple Combination Immunotherapy for Ovarian Cancer

      Rio Rancho, New Mexico
      This phase II trial studies the possible benefits of treatment with different combinations of the drugs durvalumab, olaparib and cediranib vs. the usual treatment in patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement with platinum therapy (recurrent platinum resistant). Usual treatment is the type of treatment most patients with this condition receive if they are not part of a clinical study. Combination therapies studied in this trial include MEDI4736 (durvalumab) plus olaparib and cediranib, durvalumab and cediranib, or olaparib and cediranib. Monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumors cells to grow and spread. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Cediranib may stop the growth of tumor cells by blocking VEGF (an enzyme). needed for cell growth. Giving different combinations of durvalumab, olaparib and cediranib may work better in increasing the duration of time that the cancer does not progress compared to the usual treatment.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Sex:Female

      Key Eligibility Criteria

      Disqualifiers:Platinum-refractory, Brain Metastases, Cardiac History, Others
      Must Be Taking:Bevacizumab

      120 Participants Needed

      Sotorasib for Non-Small Cell Lung Cancer

      Rio Rancho, New Mexico
      This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Leptomeningeal Disease, Cardiac Disease, Others
      Must Not Be Taking:CYP3A4 Inducers

      116 Participants Needed

      Selpercatinib for Non-Small Cell Lung Cancer

      Rio Rancho, New Mexico
      This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Leptomeningeal Disease, Brain Metastases, Cardiac Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors, Proton Pump Inhibitors

      124 Participants Needed

      Reduced-Intensity Chemoradiation for Anal Cancer

      Albuquerque, New Mexico
      This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Prior Radiation, Cardiovascular Disease, Autoimmune, Others
      Must Not Be Taking:Warfarin, Dilantin

      252 Participants Needed

      HER2-targeted Therapy + Immunotherapy for Breast Cancer

      Albuquerque, New Mexico
      A phase 2 open-label, randomized, multi-center trial to evaluate the efficacy and safety of neoadjuvant trastuzumab, pertuzumab and weekly paclitaxel (THP) as compared to neoadjuvant trastuzumab, pertuzumab, pembrolizumab and weekly paclitaxel (THP-pembrolizumab), or neoadjuvant trastuzumab, pembrolizumab and weekly paclitaxel (TH-pembrolizumab ) in chemo naive patients with invasive human epidermal growth factor receptor 2 (HER2) positive breast cancer whose primary tumors are \> 2 cm and/or clinically lymph node positive. Treatment will be followed by standard of care breast surgery and physician's choice adjuvant therapy per standard of care.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Autoimmune Disease, Cardiovascular, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids

      138 Participants Needed

      Pre- and Post-Surgery Pembrolizumab for Melanoma

      Albuquerque, New Mexico
      This phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better compared to after surgery alone in treating melanoma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Active Infection, Autoimmune, Others
      Must Not Be Taking:Immunotherapy, Biologic Therapy

      313 Participants Needed

      Why Other Patients Applied

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50
      Match to a Trial

      Radiation Therapy + Olaparib for Breast Cancer

      Albuquerque, New Mexico
      This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Infection, Heart Failure, Others
      Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers

      300 Participants Needed

      Targeted Therapy for Advanced Stage Cancer

      Rio Rancho, New Mexico
      The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers). \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:12+

      Key Eligibility Criteria

      Disqualifiers:Primary Brain Tumors, Leptomeningeal Metastases, Others
      Must Be Taking:Targeted Therapies

      4200 Participants Needed

      BB-1701 for Breast Cancer

      Albuquerque, New Mexico
      The primary purpose of the Dose Optimization (Part 1) of this study is to assess the safety and tolerability of BB-1701 and to determine the recommended dose (RD) of BB-1701 for Dose Expansion (Part 2). The primary purpose of Dose Expansion (Part 2) is to assess the antitumor activity of BB-1701 at RD in the selected population(s) of breast cancer (BC).
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Pneumonitis, Heart Failure, Others
      Must Not Be Taking:Eribulin, Corticosteroids

      135 Participants Needed

      Pentavalent Meningococcal Vaccine for Meningococcal Disease

      Albuquerque, New Mexico
      This trial is testing a new vaccine that protects against five types of meningococcal bacteria in adults and adolescents. The vaccine helps the body learn to fight off these bacteria.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2
      Age:10 - 25

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Meningitis History, Tuberculosis, Others

      1220 Participants Needed

      KHK4951 for Diabetic Macular Edema

      Albuquerque, New Mexico
      The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Proliferative Diabetic Retinopathy, Glaucoma, Others
      Must Not Be Taking:Corticosteroids, Anti-VEGF, Ozurdex, Iluvien

      150 Participants Needed

      KHK4951 for Age-Related Macular Degeneration

      Albuquerque, New Mexico
      This trial is testing special eye drops called KHK4951 to help people with a vision problem known as nAMD. The drops aim to improve vision by addressing abnormal blood vessels in the eye.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:50+

      Key Eligibility Criteria

      Disqualifiers:Glaucoma, Retinal Detachment, Others
      Must Not Be Taking:Corticosteroids, Anti-VEGF, Others

      180 Participants Needed

      Combination Antiretroviral Therapy for HIV

      Albuquerque, New Mexico
      This trial tests a new combination treatment for adults with HIV-1 who are already keeping the virus under control. The treatment uses special proteins to block the virus and a new medication to stop it from making more copies. Researchers want to see if this new approach works better than current treatments.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Immunosuppression, Hepatitis C, Hepatitis B, Others
      Must Be Taking:Antiretrovirals

      83 Participants Needed

      RNA Vaccine for Shingles

      Albuquerque, New Mexico
      This trial is testing a new shingles vaccine called VZV modRNA in healthy people aged 50-69. The vaccine uses mRNA to help the body recognize and fight the virus that causes shingles. The study aims to see how safe the vaccine is and how well it works.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:50 - 85

      Key Eligibility Criteria

      Disqualifiers:Shingles, Heart Disease, Immunodeficiency, Others
      Must Not Be Taking:Immunosuppressants, Corticosteroids, RNA Vaccines

      900 Participants Needed

      Elafibranor for Primary Sclerosing Cholangitis

      Albuquerque, New Mexico
      This trial is testing elafibranor, a medication, in people with Primary Sclerosing Cholangitis (PSC), a rare liver disease. PSC causes bile ducts to get damaged, leading to more liver problems. The study will evaluate if elafibranor is safe and effective in reducing liver inflammation and improving bile flow.
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Chronic Liver Disease, Hepatitis B, Hepatitis C, HIV, Others
      Must Be Taking:Ursodeoxycholic Acid

      68 Participants Needed

      Dato-DXd Combination Therapy for Advanced Cancers

      Albuquerque, New Mexico
      This trial is testing Dato-DXd, a targeted cancer treatment, in patients with advanced or metastatic solid tumors. The treatment aims to deliver chemotherapy directly to cancer cells, helping to kill them while reducing harm to healthy cells.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Hepatitis, HIV, Tuberculosis, Others
      Must Not Be Taking:Chloroquine, Hydroxychloroquine, Others

      582 Participants Needed

      1...567

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Los Alamos, NM pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Los Alamos, NM work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Los Alamos, NM 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Los Alamos, NM is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Los Alamos, NM several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Los Alamos, NM?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Los Alamos, NM?

      Most recently, we added Palazestrant + Ribociclib for Breast Cancer, Tulisokibart for Ankylosing Spondylitis and Glofitamab + Chemotherapy for Non-Hodgkin's Lymphoma to the Power online platform.